Ablynx successfully raises €31.5 million, in total €45 million placed

28-02-2013

GHENT, Belgium, 28 February 2013 - Ablynx [Euronext Brussels: ABLX], the biopharmaceutical company focused on the discovery and development of Nanobodies®, announces today that it has raised €31.5 million through a private placement of new shares via an accelerated bookbuilding procedure announced on Wednesday 27 February 2013 after the market closed.

The private placement has allowed Ablynx to place 4,377,919 new shares with a range of domestic and international institutional investors and qualified institutional buyers in the United States at a price of €7.2 per share, a 6.7% discount on the previous closing price. This represents 10.0% of the current number of outstanding shares and will bring the total number of shares after the issue to 48,157,116. The new shares will be admitted to trading on NYSE Euronext Brussels following their issuance, which is expected to take place on 5 March 2013.

PDF-file 395.4kb

Dutch version - French version - German version